
WHAT IS CLAIMED IS:

1. Use of Compound 1, having the formula:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM) in a subject in need thereof, wherein Compound 1 or a pharmaceutically acceptable salt thereof is to be administered in a therapeutically effective amount, which is a total daily dosage of about 1 mg to about 15 mg.

2. The use of claim **Error! Reference source not found.**, wherein said therapeutically effective amount is a total daily dosage of about 2.5 mg to about 15 mg.

3. The use of claim **Error! Reference source not found.**, wherein said Compound 1 is to be administered orally.

4. The use of claim **Error! Reference source not found.**, wherein said Compound 1 is to be administered once daily.

5. The use of claim **Error! Reference source not found.**, wherein said Compound 1 is to be administered daily for at least twelve weeks.

6. The use of claim **Error! Reference source not found.**, wherein said subject has LVEF of 55% or higher, as measured prior to treatment.

7. The use of claim 1, wherein:

(a) Compound 1 or a pharmaceutically acceptable salt thereof is to be administered as a first dose administered once daily;

(b) a measurement of a first LVEF of the subject is obtained; and

(c) administration of Compound 1 or a pharmaceutically acceptable salt thereof is to be discontinued when the first LVEF is less than 50%.

8. The use of claim 7, wherein:

(d) a measurement of a second LVEF of the subject is obtained following discontinuation of administration; and

(e) administration of Compound 1 or a pharmaceutically acceptable salt thereof is to be resumed as a second dose administered once daily when the second LVEF is greater than or equal to 50%.

9. The use of claim 8, wherein the second dose is less than the first dose.


10. The use of claim 1, wherein the subject does not receive concomitant administration of a CYP2C19 inhibitor.

11. The use of claim 10, wherein the subject does not receive concomitant administration of a strong CYP3A4 inhibitor.

12. The use of claim 1, wherein the subject does not receive concomitant administration of a strong CYP3A4 inhibitor.

13. The use of claim 1, wherein Compound 1 is in free base form.

14. Use of Compound 1, having the formula:



,

in the manufacture of a medicament for treating symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM) in a subject in need thereof, wherein Compound 1 is to be orally administered once daily in a therapeutically effective amount, which is from about 1 mg to about 15 mg.

15. The use of claim 14, wherein the therapeutically effective amount is from about 2.5 mg to about 15 mg.

16. The use of claim 14, wherein said subject has a LVEF of 55% or higher, as measured prior to treatment.

17. The use of claim 14, wherein:

(a) Compound 1 is to be administered as a first dose administered once daily;

(b) a measurement of a first LVEF of the subject is obtained; and

(c) administration of Compound 1 is to be discontinued when the first LVEF is less than 50%.

18. The use of claim 17, wherein:

(d) a measurement of a second LVEF of the subject is obtained following discontinuation of administration; and

(e) administration of Compound 1 is to be resumed as a second dose administered once daily when the second LVEF is greater than or equal to 50%.

19. The use of claim 18, wherein the second dose is less than the first dose.

20. The use of claim 14, wherein the subject does not receive concomitant administration of a CYP2C19 inhibitor.

21. The use of claim 20, wherein the subject does not receive concomitant administration of a strong CYP3A4 inhibitor.

22. The use of claim 14, wherein the subject does not receive concomitant administration of a strong CYP3A4 inhibitor.